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Abstract 
Objectives: The objectives were to 1) assess the possible impact of face-to-face patient education on Electronic Quality Improvement 
Platform for Plans and Pharmacies (EQuIPP) performance scores, 2) determine if face-to-face patient education increased overall 
knowledge and number of identified patients on statin therapy, and 3) identify barriers to statin therapy in targeted patients with 
diabetes.  
Design:  Participants received an anonymous survey tool collecting demographic data and assessing barriers, baseline knowledge, and 
perceptions about statin therapy. Following the initial survey, participants received education from the pharmacist describing the risks 
and benefits of statin therapy and were given a supplemental pamphlet. A second post-education survey tool was given to assess post-
education knowledge and perceptions. At the end of the study period, investigators assessed the number of participants started on 
statin therapy and calculated the predicted percentage change in EQuIPP score. 
Setting and Participants: This study was conducted at Waterfront Family Pharmacy in Morgantown, West Virginia from December 
2017 until April 2018. Participants were included if aged 40 to 75, received at least two fills of a diabetes medication at the pharmacy 
in the last year, had not taking a statin within a year prior to participating in the study, and could read and write in English.  
Outcome Measures: The primary outcome measure was the predicted percentage change in the “Statin Use in Diabetes” EQuIPP Score. 
Secondary measures included post-educational knowledge and perceptions of statin therapy. 
Results: During the study period, 10 participants completed the surveys and educational intervention. The predicted change in “Statin 
Use in Diabetes” EQuIPP score was an increase from 75% to 76.9% (+ 1.9%). Prior to the educational intervention, none of the 
participants could identify a benefit of statin therapy aside from lowering cholesterol. After the intervention, 80% of participants could 
identify at least one additional benefit of statin therapy. Before the intervention, 30% of participants stated they would consider taking 
a statin, which increased to 80% following the pharmacist-led education. Lastly, no participants felt they needed to be on statin therapy 
prior to the intervention. Following the intervention, 40% stated they believed they were candidates for statin therapy.  
Conclusions: Patients are willing to receive education from pharmacists about their medications and are receptive to general 
recommendations. A common modifiable barrier to statin therapy is patient knowledge, emphasizing the importance of pharmacist-
provided education. Education about statin therapy may also increase EQuIPP scores in an independent community pharmacy, leading 
to better outcomes for patients and improvement of common performance measures. Overall, it appears patients require more 
education about statin therapy and the benefit these drugs can provide aside from their cholesterol lowering properties. Pharmacist-
provided education regarding statins in patients with diabetes can increase performance measures monitored by third party payers.  
Key Words: Statin, Education, Diabetes, Quality Measures 
Background 
Diabetes is a chronic, metabolic disease characterized by 
elevated levels of blood glucose, which can lead to serious 
damage of the heart, blood vessels, eyes, kidneys, and nerves. 
Globally, the number of people with diabetes has risen from 
108 million in 1980 to 422 million in 2014, and the World Health 
Organization projects that diabetes will be the seventh leading 
cause of death by 2030.1 
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HMG-CoA reductase inhibitors, also known as statins, are 
proven to reduce the risk of cardiovascular events in patients 
with diabetes. Because of this proven benefit, the                   
American Diabetes Association and American Heart 
Association/American College of Cardiology have strong 
recommendations regarding statin therapy. These 
organizations recommend that most patients with diabetes, 
between the age of 40 and 75 and with no contraindications, be 
started on at least moderate intensity statin therapy.2-4 
Despite the proven benefit of statin therapy and 
recommendations by expert panels, its use in patients with 
diabetes remains low. According to the National Diabetes 
Statistics Report, 41.8% of adults aged 21 years or older with no 
self-reported cardiovascular disease, but who were eligible for 
statin therapy, were not on a lipid-lowering medication. For 
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adults aged 21 years or older with self-reported cardiovascular 
disease, 33.1% were not on lipid-lowering medication.5 This gap 
in care leaves a large proportion of patients with diabetes at risk 
for the development, or progression, of cardiovascular disease. 
The incidence of patients with diabetes not taking statin 
therapy could be attributed to several factors including therapy 
intolerance, contraindications, or deficits in knowledge. One 
study showed that patients have a lack of perceived benefits 
and underestimate their susceptibility to dyslipidemia-related 
complications.6 Based on this information, it appears that rates 
of statin use in patients with diabetes can be improved through 
effective patient education programs. 
 
Third party payers, including the Centers for Medicare and 
Medicaid Services (CMS), also focus on this patient population. 
CMS uses a Star Rating System to measure how well Medicare 
Advantage and Part D plans perform. Medicare evaluates how 
plans perform in several categories, including “Statin Use in 
Diabetes.” A plan’s performance rating is based on the sum of 
its providers, including pharmacies. Pharmacies are not 
assigned Star Ratings, but those that improve medication use 
and a plan’s Star Ratings can see benefits such as preferred 
pharmacy network status, leading to potential increases in 
revenue. Pharmacies can monitor the status of the Star Rating 
quality measures through the Electronic Quality Improvement 
Platform for Plans and Pharmacies (EQuIPP). EQuIPP allows 
pharmacies to track Medicare outcome measures and identify 
areas in need of improvement. The measure of “Statin Use in 
Diabetes” provides pharmacies with the percentage of 
Medicare patients with diabetes who are taking a statin. An 
EQuIPP  score of 80.3% or higher indicates pharmacies are 
meeting the requirements defined by Medicare.7-8 Using these 
tools, pharmacists can work to optimize medication therapy 
and improve cardiovascular outcomes in patients with 
diabetes.  
Objectives 
The objectives of this study were to assess the possible impact 
of face-to-face patient education on EQuIPP performance 
scores, determine if face-to-face patient education increased 
overall knowledge and number of identified patients on statin 
therapy, and identify barriers to statin therapy in targeted 
patients with diabetes. 
 
Methods 
This prospective targeted intervention study used a patient 
engagement software program called PrescribeWellness to 
identify potential participants at Waterfront Family Pharmacy 
in Morgantown, WV. This study was approved by the West 
Virginia University Institutional Review Board. This system 
identified all eligible participants, regardless of prescription 
coverage, and included those without Medicare. Participants 
were approached by investigators at the pharmacy counter 
when picking up a prescription or contacted via phone to inform 
them of the project and assess their interest in participation. 
Investigators also followed up with potential participants via 
phone if they were unable to be reached during the initial 
encounter. Data collection started on December 1st, 2017 and 
continued until April 30th, 2018. Participants between the ages 
of 40 and 75 were included if they received at least two fills of 
a diabetes medication at the pharmacy in the last year, had not 
taken a statin within a year prior to being enrolled into the 
study, and could read and write in English. Participants were 
excluded if their age was less than 40 or over 75, could not read 
or write in English, or had any apparent contraindication to 
statin therapy.  
An anonymous written pre-survey (Appendix A) was used to 
determine demographic data, health history, baseline 
knowledge about statins, previous statin use, willingness to 
start a statin, and perceptions about therapy. After completion 
of the initial survey, participants received education from the 
project’s primary investigator describing the risks and benefits 
of statin therapy. This education was consistent among 
participants, and based on a patient education pamphlet 
(Appendix B) created by investigators. After receiving 
education, participants were also given a written pamphlet 
containing the information that was discussed. After the 
educational intervention, participants received a second 
anonymous survey (Appendix C) to assess post-education 
knowledge about statin therapy, willingness to start therapy, 
and their perceptions about therapy. Following the study 
period, investigators assessed the number of participants that 
had received and filled a new prescription for a statin 
medication. Investigators also calculated the predicted 
percentage change in the “Statin Use in Diabetes” EQuIPP score 
and compiled survey responses. The predicted percentage 
change in EQuIPP scores was calculated instead of the actual 
change. This method was chosen because EQuIPP data 
reporting lags approximately 2 months behind data collection 
and is reported as a 6-month or year-to-date average. It would 
also be difficult for investigators to account for patients who 
transferred a prescription into or out of the pharmacy, which 
could affect the overall score. The score was calculated using 
the following equation:  
 
Results 
Prior to the study period, 56 participants were identified for 
inclusion. Of these participants, 10 completed the surveys and 
educational intervention resulting in a 17.8% response rate. 
The second attempt was completed prior to the end of the 
study, but was unsuccessful due to lack of interest or inability 
to make contact. Demographic data collected were as follows; 
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average age of 66 years, 8 identified as male, and 10 identified 
as Caucasian, having at least a high school education/GED, and 
having a diagnosis of diabetes.  
The “Statin Use in Diabetes” EQuIPP score is reported as a 
percentage. This score calculates the number of patients with 
Medicare and diabetes that have filled a prescription for a statin 
versus the number that have not. A total of 52 participants were 
included in the “Statin Use in Diabetes” EQuIPP score 
calculation. This differs from the original 56 identified 
participants because four were not covered by Medicare. Of the 
52 identified participants with Medicare, 13 were not taking a 
statin which resulted in an overall EQuIPP score of 75% at the 
beginning of December 2017. The predicted percentage change 
in this EQuIPP score was calculated based on the number of 
participants with Medicare taking a statin at the start of the 
study period, versus the number at the end of the study period. 
At the conclusion of this study, two participants were started 
on statin therapy. Of these participants, only one had Medicare 
and was included in the predicted percentage change in EQuIPP 
score. The predicted percentage change in the “Statin Use in 
Diabetes” EQuIPP score was +1.9% (75% to 76.9%). 
The overall intervention, including surveys and education, took 
an average of 18 minutes per participant. Prior to the 
educational intervention, participant knowledge and 
background information about statin therapy was assessed. 
This assessment found that; 70% of participants had heard of a 
medication called a statin, 30% had spoken to a healthcare 
provider about statin therapy, 80% preferred to learn about 
statins from a doctor or pharmacist, and 30%  had taken a statin 
previously and discontinued therapy due to side effects. When 
participants were asked to identify common indications for 
statin therapy, a gap in knowledge was observed. This gap in 
knowledge appeared to improve after the educational 
intervention. Patient perceptions also changed after the 
educational intervention and showed a notable shift. These 
changes in knowledge and perceptions are summarized in 
Figure 1. 
Discussion 
This study showed that, despite the proven benefit of statins 
reducing the risk of cardiovascular events in patients with 
diabetes2-4, there was still a need to provide education 
regarding therapy. The majority of participants had heard of a 
statin, but did not know it could be used for more than lowering 
cholesterol levels. This represented a gap in knowledge which 
may have led to omission of therapy. This gap represents a 
modifiable factor that could be focused on to reduce the risk of 
cardiovascular events in patients with diabetes. This study 
showed that a brief educational intervention may lead to 
increased patient knowledge, change in perceptions, and an 
increase in the number of patients with diabetes on statin 
therapy. 
Platforms like EQuIPP can help pharmacists identify patients 
with opportunities for improved care. This study showed that 
educating patients about statin therapy could increase quality 
outcome measures reported by EQuIPP. Even a small increase 
in the number of patients meeting the outcome measure could 
have a large impact on the overall score. Improvement of these 
measures could lead to more comprehensive care and a 
possible increase in revenue through meeting the quality 
outcome measures tracked by third party payers.  
Limitations to this study included the use of a non-validated 
survey and small convenience based sample. The results of this 
study may not be applicable to patients with contraindications 
or intolerances to statin therapy. A low response rate was an 
additional study limitation. Of the 56 participants identified, 
only 10 participated in the study. Of the participants that did 
not participate, 32 declined to due to time constraints or lack 
of interest, and 14 could not be reached. New or lost patients 
were not factored into the predicted EQuIPP score which could 
influence the actual score. This study used an educational 
intervention only and did not attempt to contact prescribers 
regarding statin therapy, which may have resulted in lower 
rates of newly initiated statins. This study also lacked 
generalizability to all areas of the United States since it was 
conducted at a single site, all participants identified as 
Caucasian, and a majority identified as male.   
Future studies should examine the effect of contacting 
providers as part of the intervention. These studies may also 
attempt to determine how to increase patient response rates 
to a face-to-face interaction, or create a more convenient 
method of contacting patients outside of face-to-face 
interactions. Lastly, future studies should attempt to identify 
alternative ways to improve patient education about statin 
therapy and assess knowledge gained. 
Conclusion 
In conclusion, this study identified a modifiable factor that may 
prevent patients from utilizing a therapy proven to reduce or 
prevent cardiovascular disease associated with diabetes. 
Pharmacist-provided education is well received by patients and 
can have a positive influence on knowledge and perceptions, 
leading to increased rates of statin use in patients with 
diabetes. Providing education may also have a positive impact 
on quality outcomes measures tracked by third-party payers 
through platforms like EQuIPP. Improvement of these scores 
can help to optimize patient care and potentially increase a 
pharmacy’s revenue by becoming a preferred provider in a 
third-party payer’s network.  
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Figure 1. Pre-Educational versus Post-Educational Knowledge/Perceptions about Statin     Therapy (n=10) 
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